Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2021 07:30 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021

VANCOUVER, British Columbia, June 28, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, today provided an...
June 10, 2021 07:30 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals Invited to Join International Research Consortium

VANCOUVER, British Columbia, June 10, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to...
May 14, 2021 16:30 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals Provides Update on Audited Financial Statements

VANCOUVER, British Columbia, May 14, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), provides this update on the status of the audit of its consolidated...
May 11, 2021 07:30 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce...
May 05, 2021 12:26 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements

VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), announces that further to its news release dated April 29, 2021 it has...
April 29, 2021 08:55 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), the Company announces that it has made an application to the British...
April 27, 2021 07:30 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
April 13, 2021 07:30 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals and IAG to Host a Joint Webinar, “The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer”

VANCOUVER, British Columbia, April 13, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
April 06, 2021 07:30 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals Holds Pre-Submission Meeting with the European Medicines Agency and Receives Second Prepayment of C$954,248 From a Total C$7.4 Million Grant for Development of Berubicin

VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
March 30, 2021 07:30 ET | Source: WPD Pharmaceuticals

WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates

VANCOUVER, British Columbia, March 30, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to...